56.35

0.52% 0.2093

Soleno Therapeutics Inc (SLNO)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Soleno Therapeutics Inc stock is traded at $56.35, with a volume of 171.64K. It is up +0.52% in the last 24 hours and up +13.71% over the past month. Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Previous Close:

$56.14

Open:

$56.38

24h Volume:

171.64K

Relative Volume:

0.29

Market Cap:

$2.18B

Revenue:

Net Income/Loss:

$-38.99M

P/E Ratio:

-18.60

EPS:

-3.03

Net Cash Flow:

$-24.94M

1W Performance:

+0.25%

1M Performance:

+13.71%

6M Performance:

+25.07%

1Y Performance:

+143.46%

1-Day Range:

$55.64

$56.73

1-Week Range:

$54.10

$56.73

52-Week Range:

$21.30

$57.28

Soleno Therapeutics Inc Stock (SLNO) Company Profile

Name

Soleno Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

650-213-8444

Address

203 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA

Employee

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

SLNO's Discussions on Twitter

Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-24	Initiated	Piper Sandler	Overweight
Jan-23-24	Initiated	Stifel	Buy
Nov-21-23	Resumed	Guggenheim	Buy
Sep-29-20	Initiated	Guggenheim	Buy
Jan-10-20	Initiated	Craig Hallum	Buy
Dec-23-19	Initiated	Oppenheimer	Outperform
Feb-13-18	Reiterated	Maxim Group	Buy

View All

Soleno Therapeutics Inc Stock (SLNO) Latest News

Nov 04, 2024

(SLNO) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 04, 2024

Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Target Price at $69.86 - Defense World

Nov 04, 2024

Nov 03, 2024

Emerald Advisers LLC Increases Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat

Nov 03, 2024

Nov 01, 2024

Soleno Therapeutics (NASDAQ:SLNO) Price Target Raised to $73.00 at Oppenheimer - Defense World

Nov 01, 2024

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Nov 01, 2024

Oct 29, 2024

Soleno Therapeutics (NASDAQ:SLNO) Hits New 52-Week High Following Analyst Upgrade - Defense World

Oct 29, 2024

Oct 28, 2024

Soleno Therapeutics, Inc. (NASDAQ:SLNO) Stake Boosted by Allspring Global Investments Holdings LLC - Defense World

Oct 28, 2024

Capnia Inc stock soars to 52-week high of $56.89 amid robust growth By Investing.com - Investing.com South Africa

Oct 28, 2024

Soleno Therapeutics shares remain Outperform as analyst lifts price target on updated sales projections - Investing.com Australia

Oct 28, 2024

Soleno Therapeutics (NASDAQ:SLNO) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat

Oct 28, 2024

Capnia Inc stock soars to 52-week high of $56.89 amid robust growth - Investing.com India

Oct 28, 2024

Oppenheimer Boosts Soleno Therapeutics (NASDAQ:SLNO) Price Target to $73.00 - MarketBeat

Oct 28, 2024

Soleno Therapeutics to Participate in Upcoming November Investor Conferences - GlobeNewswire

Oct 28, 2024

Oct 24, 2024

(SLNO) Technical Data - Stock Traders Daily

Oct 24, 2024

Oct 21, 2024

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. - GlobeNewswire

Oct 21, 2024

Oct 18, 2024

TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors - Barron's

Oct 18, 2024

Oct 17, 2024

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA - MSN

Oct 17, 2024

Oct 16, 2024

Prader-Willi Syndrome Market to Drive Growth with Prominent - openPR

Oct 16, 2024

Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR - Insider Monkey

Oct 16, 2024